MaxCyte.

MaxCyte. SeQure Dx, Inc. is applying state of the art genomics technologies for gene editor target profiling to advance discovery, clinical development, and diagnostic solutions. Our core technologies, GUIDE-seq and ONE-seq, enable identification of all potential off-target sites prior to initiating therapy, to allow comprehensive confirmation of actual edits. This information provides gene editing therapeutics developers, physicians and patients with the confidence needed to ensure safe and effective gene therapies.